Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VNRX
stocks logo

VNRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
990.58K
+416.84%
-0.036
-40.48%
941.25K
+276.5%
-0.048
-20.83%
3.73M
+818.08%
-0.022
-62.5%
Estimates Revision
The market is revising Downward the revenue expectations for VolitionRx Limited (VNRX) for FY2025, with the revenue forecasts being adjusted by -13.19% over the past three months. During the same period, the stock price has changed by -48.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+11.73%
In Past 3 Month
Stock Price
Go Down
down Image
-48.27%
In Past 3 Month
Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.311
sliders
Low
2.50
Averages
2.50
High
2.50
Current: 0.311
sliders
Low
2.50
Averages
2.50
High
2.50
Maxim
Buy
to
Hold
downgrade
2025-12-03
New
Reason
Maxim
Price Target
2025-12-03
New
downgrade
Buy
to
Hold
Reason
Maxim downgraded VolitionRx to Hold from Buy.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-11-17
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3 revenue that was up 32% year over year and a $5.4M net loss, while securing two notable human diagnostics agreements with Werfen and Hologic (HOLX), the analyst tells investors in a research note. With roughly 10 major diagnostics and liquid-biopsy companies engaged at various stages of partnership discussions, management expects additional licensing deals, underscoring the broad potential of the Nu.Q platform across cancer, sepsis, and epigenetic drug development, the firm says.
JonesResearch
Justin Walsh
Buy
initiated
$3
2025-06-09
Reason
JonesResearch
Justin Walsh
Price Target
$3
2025-06-09
initiated
Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2025-04-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-04-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Initiates
$2.5
2025-04-08
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-04-08
Initiates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$5
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$5
2025-04-01
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is -1.86, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.32
Current PE
-1.86
Overvalued PE
-2.20
Undervalued PE
-6.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.56
Undervalued EV/EBITDA
-4.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
170.66
Current PS
0.00
Overvalued PS
628.11
Undervalued PS
-286.78
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VNRX News & Events

Events Timeline

(ET)
2025-11-13
16:16:23
VolitionRx Announces Q3 Revenue of $600,000, Below Consensus Estimate of $715,590
select
2025-10-10 (ET)
2025-10-10
08:34:46
VolitionRx reveals pricing for $6M common stock and warrant offering
select
2025-10-09 (ET)
2025-10-09
16:06:48
VolitionRx Reveals Common Stock and Warrants Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-27Benzinga
D. Boral Capital Reiterates Buy Rating on VolitionRX with $5 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
7.5
11-25Newsfilter
VolitionRx Makes First Sale of Nu.Q® Cancer Assays to Leading French Cancer Center
  • First Order: VolitionRx successfully completes its first sale of Nu.Q® cancer assays to Hospices Civils de Lyon in France, marking a significant step in its commercialization efforts in the European market.
  • Clinical Application Outlook: The hospital plans to introduce the Nu.Q® test into routine clinical practice following internal certification, which is expected to significantly enhance cancer patient management efficiency and precision in treatment decisions.
  • Scientific Support: Research from Claude Bernard University indicates that Nu.Q® technology can provide critical information on survival and progression-free survival for non-small cell lung cancer patients by measuring methylated nucleosome biomarker levels, thereby enriching clinical prognostication.
  • Market Potential: This sale represents a major milestone for VolitionRx in the commercialization of its products in the human cancer field, further driving its growth in the cancer diagnostics market and supporting the company's mission to save lives.
[object Object]
Preview
7.5
11-14SeekingAlpha
VolitionRx Enters New Era with Partnerships Aiming for $85M APS Market and 32% Revenue Increase

  • Management Announcements: VolitionRx Limited's CEO, Cameron Reynolds, highlighted the signing of two significant agreements with Werfen and Hologic to commercialize their Nu.Q platform, targeting the antiphospholipid syndrome (APS) market, which has a total addressable market of approximately $85 million annually.

  • Financial Performance: The company reported a 32% increase in revenue for Q3 2025, totaling $0.6 million, while operating expenses decreased by 10% year-on-year, indicating progress towards cash neutrality despite the unpredictability of revenue streams.

  • Technological Advancements: Chief Scientific Officer Dr. Jacob Micallef discussed the successful submission of a paper on a new liquid biopsy method that significantly enriches cancer DNA detection, showcasing the company's innovative capabilities.

  • Market Sentiment and Future Outlook: Analysts expressed a cautiously optimistic view on VolitionRx's commercial progress and cost management, while management emphasized the importance of executing licensing agreements and maintaining discipline in financial operations to ensure sustainable growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 0.3114 USD — it has increased 9.49 % in the last trading day.

arrow icon

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

arrow icon

What is the price predicton of VNRX Stock?

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 627.28K USD, increased 32.19 % YoY.

arrow icon

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -28.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for VolitionRX Ltd (VNRX)'s fundamentals?

The market is revising Downward the revenue expectations for VolitionRx Limited (VNRX) for FY2025, with the revenue forecasts being adjusted by -13.19% over the past three months. During the same period, the stock price has changed by -48.27%.
arrow icon

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 85 emplpoyees as of December 05 2025.

arrow icon

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 37.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free